Skip to main content

Advertisement

SpringerLink
Log in

Waldenström’s Macroglobulinaemia

Current Therapy and Future Approaches

  • Therapy Review
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Waldenström’s macroglobulinaemia is a rare B-cell malignancy. It is prevalent in the sixth and seventh decades, the median age at diagnosis being 63 years. Conventional treatment has involved alkylator therapy, especially chlorambucil given daily at a low dose or intermittently at a higher dose. Purine analogues, used initially as salvage therapy in refractory disease, are increasingly used for initial therapy. However, purine analogue therapy entails significant complications, including immunosuppression, pancytopenia and autoimmune haemolysis. Moreover, it is unclear whether purine analogues extend survival. All of these need to be considered before initiation of therapy. More recently, anti-CD20 monoclonal antibody and thalidomide have been used with a 30% response in treated patients. High-dose therapy with stem cell support achieves a partial response in a majority of patients receiving this modality of therapy. The median survival of 5 years has not improved considerably since the introduction of purine analogues. Complete response is still uncommon; using all available modalities of therapy may increase the complete response rate and improve survival. Great strides in understanding the malignant cell, the microenvironment and the potential interactions have identified potential targets for therapy in multiple myeloma. These agents may also be useful in Waldenström’s macroglobulinaemia. Since this is a rare malignancy, all patients should be treated with well-designed clinical protocols to achieve improvement in outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aoki H, Takishita M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom’s macroglobulinemia and chronic lymphocytic leukemia with Richters transformation but not in common CLL. Blood 1995; 85:1913–9

    PubMed  CAS  Google Scholar 

  2. Levy Y, Fermand JP, Navrro S, et al. Interleukin 6 dependance of spontaneous in vitro differentiation of B cells from patients with IgM gammopathy. Proc Natl Acad Sci USA 1990; 87: 3309–13

    Article  PubMed  CAS  Google Scholar 

  3. Merlini G. Waldenstrom’s macroglobulinemia: clinical manifestations and prognosis. (American Society of Hematology education program book). Hematology 1999: 358-69

  4. Owen RG, Barrans SL, Richards SJ, et al. Waldenstrom macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116: 420–8

    Article  PubMed  CAS  Google Scholar 

  5. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom’s macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer 1998; 82: 1078–81

    Article  PubMed  CAS  Google Scholar 

  6. Ahmed S, Shurafa MS, Bishop CR, et al. Waldenstrom’s macroglobulinemia in African-American adults. Am J Hematol 1999; 60: 229–30

    Article  PubMed  CAS  Google Scholar 

  7. Izumi T, Sasaki R, Tsunoda S, et al. B cell malignancy and hepatitis C virus infection. Leukemia 1997; 11Suppl. 3: 516–8

    PubMed  Google Scholar 

  8. Zuckerman E, Zuckerman T, Sahar D, et al. The effect of antiviral therapy on t(14;18) translocation and immunoglobulin gene rearrangements in patients with chronic hepatitis C virus infection. Blood 2001; 97: 1555–9

    Article  PubMed  CAS  Google Scholar 

  9. Agbalika E, Mariette X, Maroulleau JP, et al. Detection of herpesvirus-8 DNA in bone marrow biopsies from patients with multiple myeloma and Waldenstrom’s macroglobulinemia. Blood 1998; 91: 4393–4

    PubMed  CAS  Google Scholar 

  10. Linet MS, Humphrey RL, Mehl ES, et al. A case-control and family study of Waldenstrom’s macroglobulinemia. Leukemia 1993; 7: 1363–9

    PubMed  CAS  Google Scholar 

  11. Ogmundsdottir HM, Sveinsdottir S, Sigfusson A, et al. Enhanced B cell survival in familial macroglobulinemia is associated with increased expression of Bcl-2. Clin Exp Immunol 1999; 117: 252–60

    Article  PubMed  CAS  Google Scholar 

  12. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors with Waldenstrom macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96: 852–8

    PubMed  CAS  Google Scholar 

  13. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003) Blood 2001; 98: 41–8

    Article  PubMed  CAS  Google Scholar 

  14. Buskard NA, Galton DAG, Goldman JM, et al. Plasma exchange in the long-term management of Waldenstrom’s macroglobulinemia. Can Med Assoc J 1977; 117: 135–7

    PubMed  CAS  Google Scholar 

  15. Humphrey JS, Lockard C. Durable complete remission of macroglobulinemia after splenectomy. Am J Hematol 1995; 48: 262–6

    Article  PubMed  CAS  Google Scholar 

  16. Kyle RA, Greipp PR, Gertz MA, et al. Waldenstrom’s macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000; 108: 737–42

    Article  PubMed  CAS  Google Scholar 

  17. Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobulinemia. Blood 1994; 83: 1452–9

    PubMed  CAS  Google Scholar 

  18. Case DC, Ervin TJ, Boyd MA. Long term results and disease characteristics of patients with Waldenstrom’s macroglobulinemia treated with the M-2 protocol [abstract]. Blood 1993; 82Suppl. 1: 561a

    Google Scholar 

  19. Dimopoulos MA, O’Brien S, Kantarjian H, et al. Fludarabine therapy in Waldenstoms macroglobulinemia. Am J Med 1993; 95: 49–52

    Article  PubMed  CAS  Google Scholar 

  20. Zinzani PL, Gherlinzoni F, Bendandi M, et al. Fludarabine treatment in resistant Waldenstrom’s macroglobulinemia. Eur J Haematol 1995; 54: 120–3

    Article  PubMed  CAS  Google Scholar 

  21. Leblond V, Ben-Othman T, Deconinck E, et al. Activity of fludarabine in previously treated Waldenstrom’s macroglobulinemia: a report of 71 cases. Groupe Cooperatif Macroglobulinemie. J. Clin Oncol 1998; 16: 2060–4

    PubMed  CAS  Google Scholar 

  22. Leblond V, Cazin B, Fermand JP, et al. Results of a multicentric randomized study comparing the efficacy of cyclophosphamide, doxorubicin and prednisone to that of fludarabine in patients with Waldenstrom’s macroglobulinemia in first relapse or primary refractory disease [abstract]. Ann Oncol 1999; 10Suppl. 3: 66

    Google Scholar 

  23. Dimopoulos MA, Weber D, Delasalle K, et al. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxy adenosine: identification of prognostic factors. Ann Oncol 1995; 6: 49–52

    PubMed  CAS  Google Scholar 

  24. Betticher DC, Hsu-Schmitz SF, Ratschiller D, et al. Cladribine (2-CDA) given, as a subcutaneous bolus injection is active in pretreated Waldenstrom’s macroglobulinaemia. Swiss group for clinical cancer research. Br J Haematol 1997; 99: 358–63

    Article  PubMed  CAS  Google Scholar 

  25. Hellmann A, Lewandowski K, Zancha AM, et al. Treatment of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine. Eur J Haematol 1999; 63:35–41

    Article  PubMed  CAS  Google Scholar 

  26. Delannoy A, Van de Neste E, Michaux JL, et al. Cladribine for Waldenstrom’s macroglobulinemia. Br J Haematol 1999; 104: 933–4

    Article  PubMed  CAS  Google Scholar 

  27. Fridrik MA, Jager B, Baldinger C, et al. First-line treatment of Waldenstrom’s disease with cladribine. Ann Hematol 1997; 74(1): 7–10

    Article  PubMed  CAS  Google Scholar 

  28. Dimopoulos MA, Kantarjian H, Weber D, et al. Primary therapy of Waldenstrom’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12:2694–8

    PubMed  CAS  Google Scholar 

  29. Foran JM, Rohatiner AZ, Coiffer B, et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom’s macroglobulinemia and mantle-cell lymphoma. J Clin Oncol 1999; 17: 546–53

    PubMed  CAS  Google Scholar 

  30. Liu F, Burian C, Miller W, et al. Bolus administration of cladribine in the treatment of Waldenstrom’s macroglobulinemia. Br J Haematol 1998; 103: 690–5

    Article  PubMed  CAS  Google Scholar 

  31. Van Den Neste E, Delannoy A, Vandercam B, et al. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235–40

    Article  Google Scholar 

  32. Tetreault SA, Saven A. Delayed onset of autoimmune hemolytic anemia complicating cladribine therapy for Waldenstrom macroglobulinemia. Leuk Lymphoma 2000; 37: 125–30

    Article  PubMed  CAS  Google Scholar 

  33. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom’s macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10: 1525–7

    Article  PubMed  CAS  Google Scholar 

  34. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317–24

    PubMed  CAS  Google Scholar 

  35. Ritucan package insert. IDEC Pharmaceutical Corporation and Genentech Inc. Revised 2001 Apr.

  36. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti CD-20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217–24

    PubMed  CAS  Google Scholar 

  37. Yang H, Rosove MH, Figlin MA. Tumor lysis syndrome after the administration of rituximab in lymphoproliferative disorders high-grade non-Hodgkins lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62: 247–50

    Article  PubMed  CAS  Google Scholar 

  38. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96: 1184–6

    PubMed  CAS  Google Scholar 

  39. Desikan R, Dhodapkar M, Siegel D, et al. High dose therapy with autologous peripheral blood stem cell support for Waldenstrom’s macroglobulinemia: a pilot study. Br J Haematol 1999; 105: 993–6

    Article  PubMed  CAS  Google Scholar 

  40. Mustafa M, Powles R, Treleaven J, et al. Total therapy with VAMP/CVAMP and high dose melphalan and autograft for IgM lymphoplasmacytoid disease [abstract]. Blood 1998; 92Suppl. 1: 281b

    Google Scholar 

  41. Dreger P, Glass B, Kuse R, et al. Myeloablative chemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom’s macroglobulinemia. Br J Haematol 1999; 106: 115–8

    Article  PubMed  CAS  Google Scholar 

  42. Levy Y, Chedeville A, Brouet JC. Effects of interferon-alpha and -gamma on B cell differentiation in macroglobulinemia. Leuk Lymphoma 1996; 23: 347–51

    Article  PubMed  CAS  Google Scholar 

  43. Rotoli B, DeRenzo A, Frigeri F, et al. A phase II trial on alpha interferon effect in patients with monoclonal IgM gammopathy. Leuk Lymphoma 1994; 13: 463–9

    Article  PubMed  CAS  Google Scholar 

  44. Queseda JR, Alexanian R, Kurzock R, et al. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma and Waldenstrom’s macroglobulinemia. Am J Hematol 1988; 29: 1–4

    Article  Google Scholar 

  45. Legouffe E, Rossi JF, Laporte JP, et al. Treatment of Waldenstrom’s macroglobulinemia with very low doses of alpha interferon. Leuk Lymphoma 1995; 19: 337–42

    Article  PubMed  CAS  Google Scholar 

  46. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase II study of 169 patients. Blood 2001; 98: 492–4

    Article  PubMed  CAS  Google Scholar 

  47. Dimopoulos MA, Zomas A, Viniou NA, et al. Treatment of Waldenstrom’s macroglobulinemia with thalidomide. J Clin Oncol 2001; 19: 3596–601

    PubMed  CAS  Google Scholar 

  48. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkins lymphoma. Lancet 1997; 349: 1137–41

    Article  PubMed  CAS  Google Scholar 

  49. Stinchcombe TE, Mitchell BS, Smith DN, et al. PS-341 is active in multiple myeloma: preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies [abstract]. Blood 2000; 96: 516a

    Google Scholar 

  50. Hideshima T, Richardson PG, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells [abstract]. Blood 2000; 96: 461a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Myeloma and Transplant Service, Saint Vincent’s Comprehensive Cancer Center, 325 W. 15th Street, New York, NY, 10011, USA

    Raman Desikan, Zujun Li & Sundar Jagannath

Authors
  1. Raman Desikan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zujun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sundar Jagannath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raman Desikan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Desikan, R., Li, Z. & Jagannath, S. Waldenström’s Macroglobulinaemia. BioDrugs 16, 201–207 (2002). https://doi.org/10.2165/00063030-200216030-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200216030-00004

Keywords

Search

Navigation